CSL News: CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) f - 24th Apr 2024, 5:00pm

[annb0t]

First non-immunosuppressive therapy for the treatment of IgA Nephropathy (IgAN) approved in Europe

Conditional marketing authorization is based on statistically significant and clinically meaningful results from the phase-III PROTECT trial

ST. GALLEN, Switzerland and SAN DIEGO, April 24, 2024 /CNW/ -- CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that the European Commission has granted conditional marketing authorization (CMA) for FILSPARI (sparsentan) f...

>>> Read more: CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy